Deficiency of Protein C or Protein S As a Possible Cause of Osteoporosis

Overview

Journal Endocrine

Specialty Endocrinology

Date 2024 Mar 14

PMID 38483687

Authors

Aleksandar Cirovic

Marija Djuric

Petar Milovanovic

Affiliations

Soon will be listed here.

Abstract

Proteins C and S are vitamin K-dependent anticoagulative factors that also exert a significant influence on bone quality. Clinical studies have linked the deficiency of proteins C and S to lower bone mineral density and the onset of femoral head osteonecrosis in children. Rare foundational studies analyzing this topic have demonstrated that activated protein C, upon binding to the endothelial protein C receptor expressed on the surface of osteoblasts, promotes osteoblast proliferation. It is also established that proteins C and S play crucial roles in proper collagen synthesis and in maintaining the number of osteoclasts and blood vessels. However, the association between protein C and/or S deficiency and the gradual onset of osteoporosis remains largely uninvestigated. Calculations based on data from peer-reviewed journals suggest that approximately one in every 10 individuals may develop osteoporosis due to congenital protein C or S deficiency. Moreover, when secondary causes of protein C and S deficiency are also considered, the proportion likely further increases. In this paper, we discuss the pathophysiological background of the potential relationship between protein C and S deficiency and the genesis of osteoporosis.

References

Tait R, Walker I, Reitsma P, Islam S, MCCALL F, Poort S . Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995; 73(1):87-93. View

Pabinger I, Kyrle P, Heistinger M, Eichinger S, Wittmann E, Lechner K . The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost. 1994; 71(4):441-5. View

Avgeri M, Papadopoulou A, Platokouki H, Douros K, Rammos S, Nicolaidou P . Assessment of bone mineral density and markers of bone turnover in children under long-term oral anticoagulant therapy. J Pediatr Hematol Oncol. 2008; 30(8):592-7. DOI: 10.1097/MPH.0b013e31817541a8. View

Rathod T, Tayade M, Shetty S, Jadhav P, Sathe A, Mohanty S . Association of Thrombophilic Factors in Pathogenesis of Osteonecrosis of Femoral Head in Indian Population. Indian J Orthop. 2020; 54(Suppl 1):33-38. PMC: 7474030. DOI: 10.1007/s43465-020-00181-9. View

Wermes C, Bergmann F, Reller B, Sykora K . Severe protein C deficiency and aseptic osteonecrosis of the hip joint: a case report. Eur J Pediatr. 2000; 158 Suppl 3:S159-61. DOI: 10.1007/pl00014345. View

Chen Y, Guo Y, Liu Y, Zhang C, Huang F, Chen L . Identification of Di/Tripeptide(s) With Osteoblasts Proliferation Stimulation Abilities of Yak Bone Collagen by Screening and Molecular Docking. Front Nutr. 2022; 9:874259. PMC: 9197386. DOI: 10.3389/fnut.2022.874259. View

Maillard C, Berruyer M, Serre C, Dechavanne M, Delmas P . Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology. 1992; 130(3):1599-604. DOI: 10.1210/endo.130.3.1531628. View

Sugiyama T, Takaki T, Sakanaka K, Sadamaru H, Mori K, Kato Y . Warfarin-induced impairment of cortical bone material quality and compensatory adaptation of cortical bone structure to mechanical stimuli. J Endocrinol. 2007; 194(1):213-22. DOI: 10.1677/JOE-07-0119. View

Maillard C, Berruyer M, Serre C, Amiral J, Dechavanne M, Delmas P . Thrombomodulin is synthesized by osteoblasts, stimulated by 1,25-(OH)2D3 and activates protein C at their cell membrane. Endocrinology. 1993; 133(2):668-74. DOI: 10.1210/endo.133.2.8393772. View

10.

Kurata T, Hayashi T, Yoshikawa T, Okamoto T, Yoshida K, Iino T . Activated protein C stimulates osteoblast proliferation via endothelial protein C receptor. Thromb Res. 2009; 125(2):184-91. DOI: 10.1016/j.thromres.2009.09.005. View

11.

Lee Y, Jeong J, Seol J, Xue M, Jackson C, Park S . Activated protein C differentially regulates both viability and differentiation of osteoblasts mediated by bisphosphonates. Exp Mol Med. 2013; 45:e9. PMC: 3584664. DOI: 10.1038/emm.2013.16. View

12.

Willett T, Dapaah D, Uppuganti S, Granke M, Nyman J . Bone collagen network integrity and transverse fracture toughness of human cortical bone. Bone. 2018; 120:187-193. PMC: 6360115. DOI: 10.1016/j.bone.2018.10.024. View

13.

Yoshida K, Akita N, Okamoto T, Asanuma K, Uchida A, Sudo A . Activated protein C suppresses osteoclast differentiation via endothelial protein C receptor, protease-activated receptor-1, sphingosine 1-phosphate receptor, and apolipoprotein E receptor 2. Thromb Res. 2018; 163:30-40. DOI: 10.1016/j.thromres.2018.01.001. View

14.

Shen K, Murphy C, Chan B, Kolind M, Cheng T, Mikulec K . Activated protein C (APC) can increase bone anabolism via a protease-activated receptor (PAR)1/2 dependent mechanism. J Orthop Res. 2014; 32(12):1549-56. DOI: 10.1002/jor.22726. View

15.

Liang X, Du Y, Wen Y, Liu L, Li P, Zhao Y . Assessing the Genetic Correlations Between Blood Plasma Proteins and Osteoporosis: A Polygenic Risk Score Analysis. Calcif Tissue Int. 2018; 104(2):171-181. PMC: 6368453. DOI: 10.1007/s00223-018-0483-4. View

16.

Pan E, Gomperts E, Millen R, Gilsanz V . Bone mineral density and its association with inherited protein S deficiency. Thromb Res. 1990; 58(3):221-31. DOI: 10.1016/0049-3848(90)90092-q. View

17.

Nalevaiko J, Marques J, Oliveira M, Raetsch A, Marques G, Petterle R . Bone density and quality in patients treated with direct-acting oral anticoagulants versus warfarin. Bone. 2021; 150:116000. DOI: 10.1016/j.bone.2021.116000. View

18.

Rezaieyazdi Z, Falsoleiman H, Khajehdaluee M, Saghafi M, Mokhtari-Amirmajdi E . Reduced bone density in patients on long-term warfarin. Int J Rheum Dis. 2010; 12(2):130-5. DOI: 10.1111/j.1756-185X.2009.01395.x. View

19.

Namba S, Yamaoka-Tojo M, Hashikata T, Ikeda Y, Kitasato L, Hashimoto T . Long-term warfarin therapy and biomarkers for osteoporosis and atherosclerosis. BBA Clin. 2015; 4:76-80. PMC: 4661704. DOI: 10.1016/j.bbacli.2015.08.002. View

20.

Kohli S, Kohli V . Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian J Endocrinol Metab. 2011; 15(3):175-81. PMC: 3156536. DOI: 10.4103/2230-8210.83401. View